If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Reabold Resources, Block Energy and Shield Therapeutics
Sachin Oza, Co-Chief Executive Officer of Reabold Resources (RBD) talks about today's spudding of the IM-1 Well in Romania plus covers other progress at the company.
Reabold Resources plc is an investing company investing in the exploration and production ("E&P") sector. The Company's investing policy is to acquire direct and indirect interests in exploration and producing projects and assets in the natural resources sector, and consideration is currently given to investment opportunities anywhere in the world. As an investor in upstream oil & gas projects, Reabold aims to create value from each project by investing in undervalued, low-risk, near-term upstream oil & gas projects and by identifying a clear exit plan prior to investment. Reabold's long term strategy is to re-invest capital made through its investments into larger projects in order to grow the Company. Reabold aims to gain exposure to assets with limited downside and high potential upside, capitalising on the value created between the entry stage and exit point of its projects. The Company invests in projects that have limited correlation to the oil price.
Paul Haywood, Chief Executive Officer of Block Energy (BLOE) provides an update on their production progress and exploration plans at West Restavi in the Republic of Georgia
Block Energy is an AIM-listed exploration and production company applying innovative technology to realise the full potential of previously discovered fields in Georgia.
(Interview starts at 10 minutes 32 seconds)
Tim Watts, Chief Financial Officer of Shield Therapeutics (STX) their interim results and progress of their lead product Feraccru®.
Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru® / Accrufer®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® / Accrufer®, is approved by the FDA, EMA and Swiss Medic for the treatment of iron deficiency in adults and is commercialised in the European Union by Norgine BV, with a US commercialisation partner currently being selected.
(Interview starts at 20 minutes 8 seconds)